AIMS: Differences in adverse drug reactions can be explained by genetic variations, especially if they determine the expression of certain protein effectors and/or drug-metabolizing enzymes. Over the last decade, several tests screening for the most frequent polymorphisms in drug-metabolizing enzymes have been marketed for research and diagnostic purposes. The aim of this study was to assess the suitability of PHARMAchip for the genotyping of polymorphisms of genes associated with drug metabolism and response as an alternative to Jurilab Ltd's DrugMEt Test. MATERIALS & METHODS: In this observational study, performed using 100 previously genotyped DNA samples, we report on common genes included in the two different tests examined: the former DrugMEt test and the recently introduced PHARMAchip test. RESULTS & CONCLUSION: Although these tests are based on different methodological approaches, we have found a high concordance of results between both methods. Some of the discrepancies between tests were related to allelic variants not monitored in a particular microarray and the quality of the genomic DNA used.
AIMS: Differences in adverse drug reactions can be explained by genetic variations, especially if they determine the expression of certain protein effectors and/or drug-metabolizing enzymes. Over the last decade, several tests screening for the most frequent polymorphisms in drug-metabolizing enzymes have been marketed for research and diagnostic purposes. The aim of this study was to assess the suitability of PHARMAchip for the genotyping of polymorphisms of genes associated with drug metabolism and response as an alternative to Jurilab Ltd's DrugMEt Test. MATERIALS & METHODS: In this observational study, performed using 100 previously genotyped DNA samples, we report on common genes included in the two different tests examined: the former DrugMEt test and the recently introduced PHARMAchip test. RESULTS & CONCLUSION: Although these tests are based on different methodological approaches, we have found a high concordance of results between both methods. Some of the discrepancies between tests were related to allelic variants not monitored in a particular microarray and the quality of the genomic DNA used.
Authors: B Almoguera; R Riveiro-Alvarez; J Lopez-Castroman; P Dorado; C Vaquero-Lorenzo; J Fernandez-Piqueras; A Llerena; F Abad-Santos; E Baca-García; R Dal-Ré; C Ayuso Journal: Pharmacogenomics J Date: 2012-01-03 Impact factor: 3.550
Authors: Francina Fonseca; Rafael de la Torre; Laura Díaz; Antonio Pastor; Elisabet Cuyàs; Nieves Pizarro; Olha Khymenets; Magí Farré; Marta Torrens Journal: PLoS One Date: 2011-05-12 Impact factor: 3.240
Authors: Elisabet Cuyàs; Antonio Verdejo-García; Ana Beatriz Fagundo; Olha Khymenets; Joan Rodríguez; Aida Cuenca; Susana de Sola Llopis; Klaus Langohr; Jordi Peña-Casanova; Marta Torrens; Rocío Martín-Santos; Magí Farré; Rafael de la Torre Journal: PLoS One Date: 2011-11-16 Impact factor: 3.240
Authors: Ricardo Pardo-Lozano; Magí Farré; Samanta Yubero-Lahoz; Brian O'Mathúna; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Klaus Langohr; Elisabet Cuyàs; Marcel lí Carbó; Rafael de la Torre Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240
Authors: Jose Rodríguez-Morató; Albert Goday; Klaus Langohr; Mitona Pujadas; Ester Civit; Clara Pérez-Mañá; Esther Papaseit; Jose Manuel Ramon; David Benaiges; Olga Castañer; Magí Farré; Rafael de la Torre Journal: Sci Rep Date: 2019-12-31 Impact factor: 4.379